🇺🇸 FDA
Patent

US 10905768

Heterocyclic degronimers for target protein degradation

granted A61KA61K31/4035A61K31/438

Quick answer

US patent 10905768 (Heterocyclic degronimers for target protein degradation) held by C4 THERAPEUTICS, INC. expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
C4 THERAPEUTICS, INC.
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4035, A61K31/438, A61K31/439, A61K31/454